<DOC>
	<DOC>NCT01610154</DOC>
	<brief_summary>1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2. There are different effects of Sitagliptin therapy on blood glucose regulation, pancreatic alpha &amp; beta cell function are different in lean (BMI&lt;25) and overweight (BMI&gt;25) Chinese type 2 diabetics. 3. The purpose of this study is to determine whether glucagon release may contribute over 30% to the hyperglycemia in Chinese type 2 diabetics.</brief_summary>
	<brief_title>Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics― the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1. Age: 25~60 years 2. Duration of disease &lt; 3 years,no drug treatment for diabetes 3. Newly diagnosed type 2 diabetic patients (fasting plasma glucose &gt; 7.0mmol/L or/and 2h postprandial blood glucose&gt;11.1mmol/L WHO 1999) 4. Fasting plasma glucose &lt; 10 mmol/L 1. Type 1 diabetes 2. DKA, infection and other stress status 3. Autoimmune disease 4. Hepatic and renal diseases</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>glucagon</keyword>
	<keyword>dipeptidyl peptidase-4 inhibitor</keyword>
</DOC>